Babesiosis, Pentamidine, and Cotrimoxazole

Raoult, Didier; Soulayrol, L; Toga, B; Dumon, H.; Casanova, P.

doi:10.7326/0003-4819-107-6-944_2

Cited by 39 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies aimed to assay the sensitivity of B. microti to fosmidomycin and FR900098 in mice and hamsters are warranted and will set the stage for the advancement of this class of compounds for the treatment of human babesiosis. The B. microti genome also encodes dihydropteroate synthase and dihydrofolate reductase enzymes that are the target of sulfadoxine and pyrimethamine, suggesting that antifolates may be useful in the treatment of human babesiosis (76). …”

Section: Resultsmentioning

confidence: 99%

Sequencing of the smallest Apicomplexan genome from the human pathogen Babesia microti†

Cornillot

Hadj-Kaddour

Dassouli

et al. 2012

Nucleic Acids Research

185

251

View full text Add to dashboard Cite

We have sequenced the genome of the emerging human pathogen Babesia microti and compared it with that of other protozoa. B. microti has the smallest nuclear genome among all Apicomplexan parasites sequenced to date with three chromosomes encoding ∼3500 polypeptides, several of which are species specific. Genome-wide phylogenetic analyses indicate that B. microti is significantly distant from all species of Babesidae and Theileridae and defines a new clade in the phylum Apicomplexa. Furthermore, unlike all other Apicomplexa, its mitochondrial genome is circular. Genome-scale reconstruction of functional networks revealed that B. microti has the minimal metabolic requirement for intraerythrocytic protozoan parasitism. B. microti multigene families differ from those of other protozoa in both the copy number and organization. Two lateral transfer events with significant metabolic implications occurred during the evolution of this parasite. The genomic sequencing of B. microti identified several targets suitable for the development of diagnostic assays and novel therapies for human babesiosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Sequencing of the smallest Apicomplexan genome from the human pathogen Babesia microti†

Cornillot

Hadj-Kaddour

Dassouli

et al. 2012

Nucleic Acids Research

185

251

View full text Add to dashboard Cite

show abstract

“…A combination of intravenous pentamidine plus oral trimethoprim-sulfamethoxazole was effective in treating a case of B. divergens infection. 42 …”

Section: Treatmentmentioning

confidence: 99%

Babesiosis

Vannier¹,

Diuk‐Wasser²,

Mamoun³

et al. 2015

Infectious Disease Clinics of North America

276

345

View full text Add to dashboard Cite

Summary Babesiosis is a worldwide tick-borne zoonosis caused by hemoprotozoan parasites of the genus Babesia. Babesia microti is the main etiologic agent of human babesiosis and is endemic in the northeastern and the upper Midwestern United States. The geographic expansion of babesiosis has followed that of Lyme disease, but has remained more restricted. The emergence of human babesiosis poses a serious health threat in highly endemic areas. Fever is the salient feature of babesiosis and often is accompanied by a series of non-specific symptoms, explaining why diagnosis may be delayed or missed. The diagnosis is confirmed by identification of babesia organisms on Giemsa stained blood smears, detection of babesia DNA by PCR, or a four-fold rise in anti-babesia antibody titers in acute and convalescent sera. The disease may be severe or fatal, particularly in patients who are otherwise healthy but older than 50 years of age, and in patients who are immunocompromised regardless of age. Most patients have complete recovery following a standard 7 to 10 day course of antimicrobial therapy.

show abstract

“…A mild infection was resolved after the use of pentamidine and cotrimoxazole (156), but because of its side effects and renal toxicity, pentamidine was not considered suitable for treatment of patients with acute intravascular hemolysis (176). Berenil, an antitrypanosomal compound known to be effective in veterinary cases, failed to cure a patient with a severe B. divergens infection (161).…”

Section: Treatmentmentioning

confidence: 99%

Babesia divergens , a Bovine Blood Parasite of Veterinary and Zoonotic Importance

et al. 2003

View full text Add to dashboard Cite

Babesia divergens is an intraerythrocytic protozoan parasite, transmitted by the tick Ixodes ricinus, and is the main agent of bovine babesiosis in Europe. It is not only a cause of significant loss to the cattle industry; it can also infect immunocompromised humans, causing medical emergencies characterized by rapid fulmination and parasitemias that may exceed 70%. The current emphasis in Europe on sustainable agriculture and extensification is likely to lead to an increase in vector tick populations with increased risk of infection. Despite the veterinary and zoonotic importance of this parasite, relatively little research has been carried out on B. divergens, and many questions regarding the parasite's epidemiology and the host's response remain unanswered. A better understanding of the species' biology and host-parasite interactions may lead to improved control mechanisms and new trends in vaccine and antibabesial drug development. This review provides the first comprehensive summary of B. divergens biology, including its morphology, life cycle, and host specificity, and the current state of knowledge of both human and bovine infections

show abstract

Babesiosis, Pentamidine, and Cotrimoxazole

Cited by 39 publications

References 3 publications

Sequencing of the smallest Apicomplexan genome from the human pathogen Babesia microti†

Sequencing of the smallest Apicomplexan genome from the human pathogen Babesia microti†

Babesiosis

Babesia divergens , a Bovine Blood Parasite of Veterinary and Zoonotic Importance

Contact Info

Product

Resources

About